

# ForPatients

by Roche

Breast Cancer HER-2 Positive Breast Neoplasms

## A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

**Trial Status**  
Completed

**Trial Runs In**  
59 Countries

**Trial Identifier**  
NCT01566721 2011-005328-17  
MO28048

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

### ***Trial Summary:***

This multicenter, two-cohort, non-randomized, open-label study will evaluate the safety and tolerability of assisted and self-administered SC Herceptin as adjuvant therapy in participants with early HER2-positive breast cancer following tumor excision. Participants will receive Herceptin 600 milligrams (mg) SC every 3 weeks for 18 cycles, either by an assisted administration using a conventional syringe and needle/vial formulation (Cohort A) or with assisted and self-administration using a single-use injection device (SID) in selected participants (Cohort B).

**Hoffmann-La Roche**  
Sponsor

**Phase 3**  
Phase

---

**NCT01566721 2011-005328-17 MO28048**  
Trial Identifiers

---

### ***Eligibility Criteria:***

**Gender**  
All

**Age**  
>=18 Years

**Healthy Volunteers**  
No

---